Trgovina Tonix Pharmaceuticals Holding Corp. - TNXP CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | 0.08 | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.025457% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.003235% | ||||||||
| Čas nočne pristojbine | 21:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Tonix Pharmaceuticals Holding Corp ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Ključni statistični podatki
| Predhodno. Zapri* | 1.86 |
| Odpri* | 1.89 |
| Enoletna sprememba* | -39.81% |
| Dnevni razpon* | 1.83 - 1.95 |
| Razpon 52 wk | 1.62-19.06 |
| Povprečni obseg (10 dni) | 326.06K |
| Povprečni obseg (3 meseci) | 4.57M |
| Tržna kapitalizacija | 19.44M |
| Razmerje P/E | -100.00K |
| Število delnic v obtoku | 10.34M |
| Prihodki | N/A |
| EPS | -18.67 |
| Dividenda (donosnost v %) | N/A |
| Beta | 2.19 |
| Datum naslednjega zaslužka | Aug 7, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 1.85 | -0.03 | -1.60% | 1.88 | 1.95 | 1.81 |
| Jun 1, 2023 | 1.86 | 0.11 | 6.29% | 1.75 | 1.86 | 1.69 |
| May 31, 2023 | 1.62 | 0.02 | 1.25% | 1.60 | 1.64 | 1.60 |
| May 30, 2023 | 1.61 | -0.03 | -1.83% | 1.64 | 1.73 | 1.59 |
| May 26, 2023 | 1.63 | -0.04 | -2.40% | 1.67 | 1.68 | 1.62 |
| May 25, 2023 | 1.68 | -0.05 | -2.89% | 1.73 | 1.73 | 1.67 |
| May 24, 2023 | 1.72 | -0.03 | -1.71% | 1.75 | 1.76 | 1.71 |
| May 23, 2023 | 1.74 | -0.12 | -6.45% | 1.86 | 2.01 | 1.74 |
| May 22, 2023 | 1.85 | 0.05 | 2.78% | 1.80 | 1.86 | 1.77 |
| May 19, 2023 | 1.80 | 0.01 | 0.56% | 1.79 | 1.82 | 1.78 |
| May 18, 2023 | 1.81 | -0.04 | -2.16% | 1.85 | 1.85 | 1.79 |
| May 17, 2023 | 1.85 | -0.04 | -2.12% | 1.89 | 2.09 | 1.82 |
| May 16, 2023 | 1.88 | 0.02 | 1.08% | 1.86 | 1.93 | 1.79 |
| May 15, 2023 | 1.87 | -0.03 | -1.58% | 1.90 | 1.99 | 1.82 |
| May 12, 2023 | 1.89 | 0.13 | 7.39% | 1.76 | 1.93 | 1.74 |
| May 11, 2023 | 1.75 | -0.09 | -4.89% | 1.84 | 1.89 | 1.74 |
| May 10, 2023 | 1.88 | -0.15 | -7.39% | 2.03 | 2.18 | 1.86 |
| May 9, 2023 | 0.39 | -0.09 | -18.75% | 0.48 | 0.48 | 0.39 |
| May 8, 2023 | 0.48 | -0.02 | -4.00% | 0.50 | 0.50 | 0.46 |
| May 5, 2023 | 0.50 | 0.01 | 2.04% | 0.49 | 0.50 | 0.48 |
Tonix Pharmaceuticals Holding Corp. Events
| Čas (UTC) (UTC) | Država | Dogodek |
|---|---|---|
| Tuesday, June 6, 2023 | ||
| Čas (UTC) (UTC) 20:15 | Država US
| Dogodek Tonix Pharmaceuticals Holding Corp at Biotechnology Industry Organization (BIO) International Convention Tonix Pharmaceuticals Holding Corp at Biotechnology Industry Organization (BIO) International ConventionForecast -Previous - |
| Monday, August 7, 2023 | ||
| Čas (UTC) (UTC) 12:30 | Država US
| Dogodek Q2 2023 Tonix Pharmaceuticals Holding Corp Earnings Release Q2 2023 Tonix Pharmaceuticals Holding Corp Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Čas (UTC) (UTC) 13:30 | Država US
| Dogodek Q3 2023 Tonix Pharmaceuticals Holding Corp Earnings Release Q3 2023 Tonix Pharmaceuticals Holding Corp Earnings ReleaseForecast -Previous - |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
| Celotni odhodki iz poslovanja | 112.091 | 92.312 | 50.511 | 28.828 | 26.322 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 30.215 | 23.474 | 14.354 | 10.636 | 8.764 |
| Raziskave in razvoj | 81.876 | 68.838 | 36.157 | 18.192 | 17.558 |
| Prihodki iz poslovanja | -112.091 | -92.312 | -50.511 | -28.828 | -26.322 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 1.873 | 0.025 | 0.048 | 0.21 | 0.233 |
| Čisti dobiček pred obdavčitvijo | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
| Čisti dobiček po davkih | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
| Čisti dobiček pred dodatnimi postavkami | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
| Čisti dobiček | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 |
| Popravljen čisti dobiček | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 |
| Popravljene ponderirane povprečne delnice | 5.71825 | 1.80108 | 0.47296 | 0.00804 | 0.00055 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -20.4393 | -51.2399 | -110.314 | -3865.8 | -53623 |
| Popravljen normalizirani dobiček na enoto čistega dobička | -20.4393 | -51.2399 | -110.314 | -3865.8 | -53623 |
| Skupaj izredne postavke | |||||
| Dividends per Share - Common Stock Primary Issue | |||||
| Total Adjustments to Net Income | -6.659 | 0 | -1.711 | -2.474 | -3.266 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Skupni prihodki | 0 | 0 | 0 | 0 | 0 |
| Celotni odhodki iz poslovanja | 33.902 | 32.728 | 29.591 | 23.336 | 26.436 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 7.391 | 8.054 | 7.39 | 6.757 | 8.014 |
| Raziskave in razvoj | 26.511 | 24.674 | 22.201 | 16.579 | 18.422 |
| Prihodki iz poslovanja | -33.902 | -32.728 | -29.591 | -23.336 | -26.436 |
| Prihodki (odhodki) od obresti, neto Neoperativni | 0.897 | 1.048 | 0.61 | 0.196 | 0.019 |
| Čisti dobiček pred obdavčitvijo | -33.005 | -31.68 | -28.981 | -23.14 | -26.417 |
| Čisti dobiček po davkih | -33.005 | -31.68 | -28.981 | -23.14 | -26.417 |
| Čisti dobiček pred dodatnimi postavkami | -33.005 | -31.68 | -28.981 | -23.14 | -26.417 |
| Čisti dobiček | -33.005 | -31.68 | -28.981 | -23.14 | -26.417 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -33.005 | -34.084 | -28.981 | -27.395 | -26.417 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -33.005 | -34.084 | -28.981 | -27.395 | -26.417 |
| Popravljen čisti dobiček | -33.005 | -34.084 | -28.981 | -27.395 | -26.417 |
| Popravljene ponderirane povprečne delnice | 10.1365 | 9.88108 | 6.71109 | 3.5847 | 2.6103 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -3.25607 | -3.44942 | -4.31838 | -7.6422 | -10.1203 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Popravljen normalizirani dobiček na enoto čistega dobička | -3.25607 | -3.44942 | -4.31838 | -7.6422 | -10.1203 |
| Total Adjustments to Net Income | -2.404 | 0 | -4.255 |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 130.777 | 189.049 | 87.989 | 13.948 | 26.056 |
| Denarna sredstva in kratkoročne naložbe | 120.229 | 178.66 | 77.068 | 11.249 | 25.034 |
| Denarna sredstva in ustrezniki | 120.229 | 178.66 | 77.068 | 11.249 | 25.034 |
| Kratkoročne naložbe | |||||
| Prepaid Expenses | 10.548 | 10.389 | 10.921 | 2.699 | 1.022 |
| Total Assets | 225.69 | 240.9 | 98.183 | 14.558 | 26.319 |
| Property/Plant/Equipment, Total - Net | 94.529 | 51.472 | 9.829 | 0.39 | 0.043 |
| Property/Plant/Equipment, Total - Gross | 96.182 | 51.872 | 10.179 | 0.713 | 0.34 |
| Accumulated Depreciation, Total | -1.653 | -0.4 | -0.35 | -0.323 | -0.297 |
| Intangibles, Net | 0.12 | 0.12 | 0.12 | 0.12 | |
| Other Long Term Assets, Total | 0.384 | 0.259 | 0.245 | 0.1 | 0.1 |
| Total Current Liabilities | 18.18 | 21.716 | 9.819 | 5.135 | 2.655 |
| Accounts Payable | 8.068 | 13.282 | 4.598 | 3.07 | 1.404 |
| Accrued Expenses | 6.18 | 4.929 | 2.6 | 1.042 | 0.614 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 18.508 | 22.183 | 10.535 | 5.141 | 2.655 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.328 | 0.467 | 0.716 | 0.006 | 0 |
| Total Equity | 207.182 | 218.717 | 87.648 | 9.417 | 23.664 |
| Common Stock | 0.076 | 0.496 | 0.206 | 0.009 | 0.003 |
| Additional Paid-In Capital | 677.311 | 578.133 | 355.037 | 226.524 | 212.154 |
| Retained Earnings (Accumulated Deficit) | -470.038 | -359.82 | -267.533 | -217.07 | -188.452 |
| Other Equity, Total | -0.167 | -0.092 | -0.062 | -0.046 | -0.041 |
| Total Liabilities & Shareholders’ Equity | 225.69 | 240.9 | 98.183 | 14.558 | 26.319 |
| Total Common Shares Outstanding | 12.2366 | 2.48123 | 1.03004 | 0.04266 | 0.00163 |
| Other Current Liabilities, Total | 3.932 | 3.505 | 2.621 | 1.023 | 0.637 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 83.726 | 130.777 | 151.139 | 191.747 | 152.989 |
| Denarna sredstva in kratkoročne naložbe | 71.975 | 120.229 | 139.978 | 145.478 | 140.435 |
| Denarna sredstva in ustrezniki | 71.975 | 120.229 | 139.978 | 145.478 | 140.435 |
| Prepaid Expenses | 11.751 | 10.548 | 11.161 | 14.769 | 12.554 |
| Total Assets | 179.088 | 225.69 | 242.646 | 276.165 | 223.716 |
| Property/Plant/Equipment, Total - Net | 94.977 | 94.529 | 91.147 | 84.039 | 70.348 |
| Property/Plant/Equipment, Total - Gross | 97.523 | 96.182 | 91.964 | 84.604 | 70.811 |
| Accumulated Depreciation, Total | -2.546 | -1.653 | -0.817 | -0.565 | -0.463 |
| Intangibles, Net | |||||
| Other Long Term Assets, Total | 0.385 | 0.384 | 0.36 | 0.379 | 0.379 |
| Total Current Liabilities | 13.073 | 18.18 | 13.34 | 15.909 | 15.354 |
| Accounts Payable | 8.016 | 8.068 | 4.556 | 9.568 | 9.397 |
| Accrued Expenses | 5.057 | 10.112 | 8.784 | 6.341 | 5.957 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.661 | 18.508 | 13.722 | 16.383 | 15.759 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.588 | 0.328 | 0.382 | 0.474 | 0.405 |
| Total Equity | 165.427 | 207.182 | 228.924 | 259.782 | 207.957 |
| Common Stock | 0.064 | 0.076 | 0.053 | 0.032 | 0.553 |
| Additional Paid-In Capital | 682.566 | 677.311 | 667.389 | 637.77 | 593.759 |
| Retained Earnings (Accumulated Deficit) | -516.992 | -470.038 | -438.358 | -409.377 | -386.237 |
| Other Equity, Total | -0.211 | -0.167 | -0.16 | 31.357 | -0.118 |
| Total Liabilities & Shareholders’ Equity | 179.088 | 225.69 | 242.646 | 276.165 | 223.716 |
| Total Common Shares Outstanding | 10.19 | 12.2366 | 8.53144 | 5.07072 | 2.76414 |
| Redeemable Preferred Stock | |||||
| Other Current Assets, Total | 31.5 |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Čisti prihodki/začetna postavka | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
| Denarna sredstva iz poslovanja | -98.053 | -75.557 | -48.566 | -26.683 | -23.971 |
| Denarna sredstva iz poslovanja | 1.253 | 0.05 | 0.027 | 0.026 | 0.054 |
| Nedenarne postavke | 10.914 | 10.899 | 4.236 | 1.457 | 1.627 |
| Spremembe v obratnem kapitalu | -0.002 | 5.781 | -2.366 | 0.452 | 0.437 |
| Denarna sredstva pri naložbenju | -48.147 | -35.307 | -8.564 | -0.017 | -0.006 |
| Kapitalski izdatki | -48.147 | -35.307 | -8.564 | -0.017 | -0.006 |
| Celotne druge postavke denarnih tokov pri naložbenju | 0 | ||||
| Denarna sredstva pri financiranju | 87.844 | 212.487 | 123.105 | 12.919 | 23.539 |
| Izdaja (odplačilo) delnic, neto | 87.844 | 212.487 | 123.105 | 12.919 | 23.539 |
| Učinki deviznih tečajev | -0.074 | -0.031 | -0.016 | -0.004 | -0.013 |
| Neto sprememba denarnih sredstev | -58.43 | 101.592 | 65.959 | -13.785 | -0.451 |
| Cash Taxes Paid | 0 | 0.082 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -33.005 | -110.218 | -78.538 | -49.557 | -26.417 |
| Cash From Operating Activities | -32.911 | -98.053 | -75.752 | -52.217 | -31.046 |
| Cash From Operating Activities | 0.893 | 1.253 | 0.417 | 0.165 | 0.063 |
| Non-Cash Items | 2.794 | 10.914 | 8.198 | 5.433 | 2.62 |
| Changes in Working Capital | -3.593 | -0.002 | -5.829 | -8.258 | -7.312 |
| Cash From Investing Activities | -3.799 | -48.147 | -43.476 | -34.656 | -20.217 |
| Capital Expenditures | -3.799 | -48.147 | -43.476 | -34.656 | -20.217 |
| Cash From Financing Activities | -11.5 | 87.844 | 80.615 | 85.24 | 13.063 |
| Issuance (Retirement) of Stock, Net | -11.5 | 87.844 | 80.615 | 85.24 | 13.063 |
| Foreign Exchange Effects | -0.043 | -0.074 | -0.069 | -0.049 | -0.025 |
| Net Change in Cash | -48.253 | -58.43 | -38.682 | -1.682 | -38.225 |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group535K+
Borzni posredniki
87K+
Aktivne stranke mesečno
$113M+
Mesečni obseg naložb
$64M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
Trgovalna provizija
0
- 1:1
Vzvod
1:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
Tonix Pharmaceuticals Holding Corp. Company profile
O družbi Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. (Tonix) je biofarmacevtsko podjetje v klinični fazi. Osredotoča se na odkrivanje, licenciranje, pridobivanje in razvoj majhnih molekul in bioloških zdravil za zdravljenje in preprečevanje človeških bolezni ter lajšanje trpljenja. Tonixov portfelj sestavljajo predvsem kandidati za izdelke s področja imunologije, centralnega živčnega sistema (CNS) in nalezljivih bolezni. Njegov imunološki portfelj vključuje biološka zdravila za zdravljenje zavrnitve presajenih organov, avtoimunskih bolezni in raka. Portfelj CNS vključuje majhne molekule in biološka zdravila za zdravljenje bolečine, nevroloških in psihiatričnih bolezni ter odvisnosti. Portfelj kandidatov za izdelke za nalezljive bolezni vključuje cepiva za preprečevanje COVID-19, protivirusno zdravilo za zdravljenje COVID-19 in zdravljenje dolgotrajne COVID. Portfelj za nalezljive bolezni vključuje tudi cepivo v razvoju za preprečevanje noric in opičjih ošpic. Kandidatski izdelki vključujejo TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR in TNX-1900.
| Industry: | Bio Therapeutic Drugs |
26 Main Street, Suite 101
CHATHAM
NEW JERSEY 07928
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 535.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com